The results show that silymarin might be involved in the protective effects of NAFLD by up-regulating the protein expression of AKT1 and down-regulating the protein expressions of IL-6, MAPK1, Caspase 3, p53, and VEGFA. This evidence concerns the gene MAPK1 and metabolic dysfunction-associated steatotic liver disease.